The US Food and Drug Administration (FDA) yesterday approved an inhalation spray version of tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for maintenance treatment of chronic obstructive ...

BARCELONA, Spain — The risk for mortality in chronic obstructive pulmonary disease (COPD) patients being treated with tiotropium is the same whether the drug is delivered by the Respimat Soft Mist ...

Please provide your email address to receive an email when new articles are posted on . Boehringer Ingelheim Pharmaceuticals announced that the FDA has agreed to review its new drug application for ...

Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials ...

In addition to the new exacerbation data, the indication for Stiolto Respimat has been revised. The Food and Drug Administration (FDA) has approved updated labeling for Stiolto Respimat (tiotropium ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Once-daily tiotropium bromide as an add-on to inhaled corticosteroid therapy demonstrated ...

Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...

LONDON & INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma ® trial that showed adding tiotropium Respimat ® to maintenance ...

RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term ...

SAN ANTONIO, Texas--(BUSINESS WIRE)--Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite ...

New analyses show improved lung function * and asthma symptom control and reduced asthma exacerbations for patients with allergic asthma 1,2,3 These analyses evaluated the safety and efficacy of ...

Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma ® trial that showed adding tiotropium Respimat ® to maintenance asthma therapy significantly improved lung ...